Losartan prevents acquired epilepsy via TGF-β signaling suppression

Annals of Neurology

Volumn 75, Issue 6, 2014, Pages 864-875

  Bar Klein, Guy ^a   Cacheaux, Luisa P ^b,d   Kamintsky, Lyn ^a   Prager, Ofer ^a   Weissberg, Itai ^a   Schoknecht, Karl ^c   Cheng, Paul ^b   Kim, Soo Young ^b   Wood, Lydia ^b   Heinemann, Uwe ^c   Kaufer, Daniela ^b   Friedman, Alon ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; LOSARTAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL INJURY; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ELECTROCORTICOGRAPHY; EMBRYO; EPILEPSY; EPILEPTOGENESIS; FLUORESCENCE IMAGING; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SEIZURE; SINGLE DRUG DOSE;

ANIMALS; ANIMALS, NEWBORN; ANTICONVULSANTS; ASTROCYTES; BENZAMIDES; BLOOD-BRAIN BARRIER; CELLS, CULTURED; CEREBRAL CORTEX; DIOXOLES; DISEASE MODELS, ANIMAL; EMBRYO, MAMMALIAN; ENDOCYTOSIS; EPILEPSY; LOSARTAN; MALE; NEURONS; PHOSPHOPYRUVATE HYDRATASE; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84903722518     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24147     Document Type: Article

References (63)

1. Friedman A, Kaufer D, Heinemann U,. Blood-brain barrier breakdown-inducing astrocytic transformation: novel targets for the prevention of epilepsy. Epilepsy Res 2009; 85: 142-149.
2. Herman ST,. Epilepsy after brain insult: targeting epileptogenesis. Neurology 2002; 59 (suppl 5): S21-S26.
3. Shinnar S, Berg AT, O'Dell C, et al. Predictors of multiple seizures in a cohort of children prospectively followed from the time of their first unprovoked seizure. Ann Neurol 2000; 48: 122-123.
4. Tomkins O, Kaufer D, Korn A, et al. Frequent blood-brain barrier disruption in the human cerebral cortex. Cell Mol Neurobiol 2001; 21: 675-691.
5. Neuwelt EA,. Mechanisms of disease: the blood-brain barrier. Neurosurgery 2004; 54: 131-142.
6. Oby E, Janigro D,. The blood-brain barrier and epilepsy. Epilepsia 2006; 47: 1761-1774.
7. Abbott NJ, Rönnbäck L, Hansson E,. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53.
8. Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier. Neurobiol Dis 2010; 37: 13-25.
9. Abbott NJ, Friedman A,. Overview and introduction: the blood-brain barrier in health and disease. Epilepsia 2012; 53 (suppl 6): 1-6.
10. Seiffert E, Dreier JP, Ivens S, et al. Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex. J Neurosci 2004; 24: 7829-7836.
11. Ivens S, Kaufer D, Flores LP, et al. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain 2007; 130: 535-547.
12. Cacheaux LP, Ivens S, David Y, et al. Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. J Neurosci 2009; 29: 8927-8935.
13. Massagué J,. How cells read TGF-β signals. Nat Rev Mol Cell Biol 2000; 1: 169-178.
14. Shi Y, Massagué J,. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
15. König HG, Kögel D, Rami A, Prehn JH,. TGF-beta1 activates two distinct type I receptors in neurons: implications for neuronal NF-kappaB signaling. J Cell Biol 2005; 168: 1077-1086.
16. Horbelt D, Denkis A, Knaus P,. A portrait of transforming growth factor β superfamily signalling: background matters. Int J Biochem Cell Biol 2012; 44: 469-474.
17. Massague J,. TGFβ signalling in context. Nat Rev Mol Cell Biol 2012; 13: 616-630.
18. David Y, Cacheaux LP, Ivens S, et al. Astrocytic dysfunction in epileptogenesis: consequence of altered potassium and glutamate homeostasis? J Neurosci 2009; 29: 10588-10599.
19. Kaufer D, Ogle WO, Pincus ZS, et al. Restructuring the neuronal stress response with anti-glucocorticoid gene delivery. Nat Neurosci 2004; 7: 947-953.
20. Yumoto R, Nishikawa H, Okamoto M, et al. Clathrin-mediated endocytosis of FITC-albumin in alveolar type II epithelial cell line RLE-6TN. Am J Physiol Lung Cell Mol Physiol 2006; 290: L946-L955.
21. Zhao S, Fernald RD,. Comprehensive algorithm for quantitative real-time polymerase chain reaction. J Comput Biol 2005; 12: 1047-1064.
22. Bastlund JF, Jennum P, Mohapel P, et al. Measurement of cortical and hippocampal epileptiform activity in freely moving rats by means of implantable radiotelemetry. J Neurosci Methods 2004; 138: 65-72.
23. Timofeeva OA, Gordon CJ,. Changes in EEG power spectra and behavioral states in rats exposed to the acetylcholinesterase inhibitor chlorpyrifos and muscarinic agonist oxotremorine. Brain Res 2001; 893: 165-177.
24. Levi H, Schoknecht K, Prager O, et al. Stimulation of the sphenopalatine ganglion induces reperfusion and blood-brain barrier protection in the photothrombotic stroke model. PLoS One 2012; 7: e39636.
25. Ketzef M,. Compensatory network alterations upon onset of epilepsy in synapsin triple knock-out mice. Neuroscience 2011; 189: 108-122.
26. Becker AJ, Pitsch J, Sochivko D, et al. Transcriptional upregulation of Cav3.2 mediates epileptogenesis in the pilocarpine model of epilepsy. J Neurosci 2008; 28: 13341-13353.
27. Weissberg I, Reichert A, Heinemann U, Friedman A,. Blood-brain barrier dysfunction in epileptogenesis of the temporal lobe. Epilepsy Res Treat 2011;2011: 1-10.
28. Whitney AW,. A direct method of nonparametric measurement selection. IEEE Trans Comput 1971; 100: 1100-1103.
29. Rumelhart DE, Hinton GE, Williams RJ,. Learning representations by back-propagating errors. Nature 1986; 323: 533-536.
30. Powell MJ,. Restart procedures for the conjugate gradient method. Math Program 1977; 12: 241-254.
31. Prager O, Chassidim Y, Klein C, et al. Dynamic in vivo imaging of cerebral blood flow and blood-brain barrier permeability. Neuroimage 2010; 49: 337-344.
32. Tomkins O, Friedman O, Ivens S, et al. Blood-brain barrier disruption results in delayed functional and structural alterations in the rat neocortex. Neurobiol Dis 2007; 25: 367-377.
33. Van Vliet EA, da Costa Araújo S, Redeker S, et al. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007; 130: 521-534.
34. Matsuyama S, Iwadate M, Kondo M, et al. SB-431542 and Gleevec Inhibit Transforming Growth Factor-β-Induced Proliferation of Human Osteosarcoma Cells. Cancer Res 2003; 63: 7791-7798.
35. Heldin CH, Miyazono K, Ten Dijke P,. TGF-beta signaling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-471.
36. Campistol JM, Iñigo P, Jimenez W, et al. Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999; 56: 714-719.
37. Khalil A, Tullus K, Bakhiet M, et al. Angiotensin II type 1 receptor antagonist (losartan) down-regulates transforming growth factor-beta in experimental acute pyelonephritis. J Urol 2000; 164: 186-191.
38. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic ardiomyopathy. Circulation 2001; 103: 789-791.
39. Lavoie P, Robitaille G, Agharazii M, et al. Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats. J Hypertens 2005; 23: 1895-1903.
40. Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007; 13: 204-210.
41. Kaur K, Sharma AK, Singal PK,. Significance of changes in TNF-alpha and IL-10 levels in the progression of heart failure subsequent to myocardial infarction. Am J Physiol Heart Circ Physiol 2006; 291: H106-H113.
42. Huang BS, Ahmad M, Tan J, Leenen FH,. Chronic central versus systemic blockade of AT(1) receptors and cardiac dysfunction in rats post-myocardial infarction. Am J Physiol Heart Circ Physiol 2009; 297: H968-H975.
43. Löscher W, Klitgaard H, Twyman RE, Schmidt D,. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 2013; 12: 757-776.
44. Shlosberg D, Benifla M, Kaufer D, Friedman A,. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol 2010; 6: 393-403.
45. Vezzani A, French J, Bartfai T, Baram TZ,. The role of inflammation in epilepsy. Nat Rev Neurol 2011; 7: 31-40.
46. Nakashima K, Yanagisawa M, Arakawa H, et al. Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science 1999; 284: 479-482.
47. Fukuda S, Abematsu M, Mori H, et al. Potentiation of astrogliogenesis by STAT3-mediated activation of bone morphogenetic protein-Smad signaling in neural stem cells. Mol Cell Biol 2007; 27: 4931-4937.
48. Wu X, Kihara T, Hongo H, et al. Angiotensin receptor type 1 antagonists protect against neuronal injury induced by oxygen-glucose depletion. Br J Pharmacol 2010; 161: 33-50.
49. Füchtbauer L, Groth-Rasmussen M, Holm TH, et al. Angiotensin II type 1 receptor (AT1) signaling in astrocytes regulates synaptic degeneration-induced leukocyte entry to the central nervous system. Brain Behav Immun 2011; 25: 897-904.
50. Lanz TV, Ding Z, Ho PP, et al. Angiotensin II sustains brain inflammation in mice via TGF. J Clin Invest 2010; 120: 2782-2794.
51. Pereira MG, Becari C, Oliveira JA, et al. Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy. Clin Sci (Lond) 2010; 119: 477-482.
52. Łukawski K, Janowska A, Jakubus T, et al. Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock. Eur J Pharmacol 2010; 640: 172-177.
53. Ferrari G, Cook BD, Terushkin V, et al. Transforming growth factor-beta 1 (TGF-beta1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis. J Cell Physiol 2009; 219: 449-458.
54. Suzuki Y, Ito Y, Mizuno M, et al. Transforming growth factor-β induces vascular endothelial growth factor-C expression leading to lymphangiogenesis in rat unilateral ureteral obstruction. Kidney Int 2012; 81: 1-15.
55. Argaw A, Asp L, Zhang J, et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 2012; 122: 2454-2468.
56. Ferrari G, Terushkin V, Wolff MJ, et al. TGF-β1 induces endothelial cell apoptosis by shifting VEGF activation of p38MAPK from the prosurvival p38β to proapoptotic p38. Mol Cancer Res 2012; 10: 605-614.
57. Kucuk M, Kaya M, Kalayci R, et al. Effects of losartan on the blood-brain barrier permeability in long-term nitric oxide blockade-induced hypertensive rats. Life Sci 2002; 71: 937-946.
58. Kaya M, Kalayci R, Küçük M, et al. Effect of losartan on the blood-brain barrier permeability in diabetic hypertensive rats. Life Sci 2003; 73: 3235-3244.
59. Marchi N, Granata T, Alexopoulos A, Janigro D,. The blood-brain barrier hypothesis in drug-resistant epilepsy. Brain 2012; 135: e211.
60. Librizzi L, Noè F, Vezzani A, et al. Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage. Ann Neurol 2012; 72: 82-90.
61. Friedman A,. Blood-brain barrier dysfunction, status epilepticus, seizures, and epilepsy: a puzzle of a chicken and egg? Epilepsia 2011; 52 (suppl 8): 19-20.
62. Janigro D,. Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood-brain barrier. Epilepsia 2012; 53 (suppl 1): 26-34.
63. Ding G, Jiang Q, Li L, et al. Detection of BBB disruption and hemorrhage by Gd-DTPA enhanced MRI after embolic stroke in rat. Brain Res 2006; 1114: 195-203.